Source comparison
CJC-1295 vs GHRP-2: Which Peptide Wins? | Real Peptides
A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 increased baseline IGF-1 levels by 60% over 28 days. But only when subjects maintained sleep hygiene protocols that preserved endogenous GH pulse architecture. GHR
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 increased baseline IGF-1 levels by 60% over 28 days. But only when subjects maintained sleep hygiene protocols that preserved endogenous GH pulse architecture. GHRP-2 acetate, by contrast, amplified pulse frequency independent of circadian timing, elevating IGF-1 by 50–110% even in sleep-deprived cohorts. The mechanism behind this difference matters: CJC-1295 binds covalently to serum albumin, extending its half-life to 6–8 days; GHRP-2 mimics ghrelin receptor activation, triggering immediate GH secretion with a 30-minute plasma peak.
- Our team has worked with hundreds of researchers navigating this exact decision. The gap between choosing the right compound and wasting months on suboptimal protocols comes down to understanding pulse dynamics. Something most comparison guides skip entirely.
- What's the core difference between CJC-1295 and GHRP-2 Acetate for research applications?
- CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that extends GH pulse amplitude and duration through albumin binding, maintaining elevated plasma levels for 6–8 days. GHRP-2 Acetate is a growth hormone secretagogue (GHS) that increases pulse frequency by activating ghrelin receptors, triggering rapid GH release within 30 minutes. Both elevate IGF-1 by 50–200% depending on dose and protocol design, but CJC-1295 delivers sustained baseline elevation while GHRP-2 produces acute pulses. Stacking both compounds yields synergistic effects that isolated protocols cannot replicate.
- Yes, both peptides elevate growth hormone. But the mechanisms operate on entirely different timescales and receptor pathways. CJC-1295 modifies the GHRH molecule to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), allowing it to persist in circulation and sustain GH pulse amplitude over multiple days. GHRP-2, conversely, binds to the growth hormone secretagogue receptor 1a (GHS-R1a). The same receptor ghrelin activates. To trigger rapid, high-amplitude GH secretion that peaks within 30 minutes and clears within 2–4 hours. This article covers receptor selectivity differences, optimal dosing windows, documented IGF-1 response curves, reconstitution stability challenges unique to each compound, and the specific research contexts where one compound demonstrably outperforms the other.